StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research note released on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
Shares of Galmed Pharmaceuticals stock opened at $4.20 on Tuesday. Galmed Pharmaceuticals has a fifty-two week low of $2.73 and a fifty-two week high of $23.80. The company has a market cap of $21.19 million, a P/E ratio of -1.75 and a beta of 0.67. The firm has a 50-day simple moving average of $4.67 and a two-hundred day simple moving average of $4.36.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last released its quarterly earnings results on Wednesday, August 28th. The biopharmaceutical company reported $2.16 earnings per share for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Featured Articles
- Five stocks we like better than Galmed Pharmaceuticals
- What Are Some of the Best Large-Cap Stocks to Buy?
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- What is the NASDAQ Stock Exchange?
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
